Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 11 | 2025 | 167 | 1.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2025 | 469 | 1.150 |
Why?
|
| Endometrial Neoplasms | 4 | 2025 | 68 | 0.880 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2025 | 251 | 0.610 |
Why?
|
| Immunoconjugates | 3 | 2025 | 96 | 0.480 |
Why?
|
| Bevacizumab | 4 | 2025 | 60 | 0.460 |
Why?
|
| Maytansine | 2 | 2024 | 6 | 0.430 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2013 | 30 | 0.390 |
Why?
|
| Carcinoma | 1 | 2013 | 131 | 0.370 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2013 | 129 | 0.370 |
Why?
|
| Thiones | 1 | 2008 | 4 | 0.290 |
Why?
|
| Chromans | 1 | 2008 | 16 | 0.290 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 60 | 0.280 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 85 | 0.270 |
Why?
|
| Paclitaxel | 5 | 2025 | 104 | 0.270 |
Why?
|
| Folate Receptor 1 | 2 | 2024 | 3 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 142 | 0.270 |
Why?
|
| Carboplatin | 4 | 2025 | 47 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2024 | 267 | 0.250 |
Why?
|
| Camptothecin | 1 | 2025 | 30 | 0.230 |
Why?
|
| Cisplatin | 2 | 2024 | 150 | 0.220 |
Why?
|
| Vulvar Neoplasms | 1 | 2024 | 11 | 0.210 |
Why?
|
| Deoxycytidine | 1 | 2024 | 45 | 0.210 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2024 | 39 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 368 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2015 | 149 | 0.190 |
Why?
|
| Female | 17 | 2025 | 34182 | 0.160 |
Why?
|
| Quality of Life | 2 | 2025 | 1277 | 0.150 |
Why?
|
| Aged | 11 | 2025 | 14965 | 0.150 |
Why?
|
| Middle Aged | 11 | 2025 | 18314 | 0.120 |
Why?
|
| Humans | 18 | 2025 | 65676 | 0.120 |
Why?
|
| Adult | 10 | 2025 | 17481 | 0.120 |
Why?
|
| Uterine Neoplasms | 1 | 2015 | 36 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2009 | 92 | 0.110 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 548 | 0.100 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 5621 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2025 | 165 | 0.100 |
Why?
|
| Sterilization, Tubal | 1 | 2012 | 11 | 0.090 |
Why?
|
| Patient Selection | 1 | 2015 | 488 | 0.090 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2012 | 29 | 0.090 |
Why?
|
| Vaginal Smears | 1 | 2012 | 59 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2025 | 270 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 466 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2023 | 750 | 0.080 |
Why?
|
| Physicians | 1 | 2015 | 491 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 361 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 326 | 0.070 |
Why?
|
| Thymidine Phosphorylase | 1 | 2008 | 4 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 208 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2008 | 198 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 881 | 0.060 |
Why?
|
| Microsatellite Instability | 1 | 2025 | 3 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 591 | 0.060 |
Why?
|
| DNA Mismatch Repair | 1 | 2025 | 35 | 0.060 |
Why?
|
| Infusions, Parenteral | 2 | 2019 | 22 | 0.050 |
Why?
|
| Platinum | 1 | 2024 | 20 | 0.050 |
Why?
|
| Maintenance Chemotherapy | 1 | 2024 | 16 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 301 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2008 | 1043 | 0.050 |
Why?
|
| Cell Line | 1 | 2008 | 2071 | 0.050 |
Why?
|
| Platinum Compounds | 1 | 2023 | 1 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 1608 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 77 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2023 | 104 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2025 | 6901 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 218 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 12 | 0.040 |
Why?
|
| Prognosis | 1 | 2025 | 1792 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 102 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 394 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2023 | 523 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 178 | 0.040 |
Why?
|
| Organoplatinum Compounds | 2 | 2008 | 23 | 0.040 |
Why?
|
| Young Adult | 2 | 2021 | 4860 | 0.030 |
Why?
|
| Adolescent | 2 | 2021 | 6409 | 0.030 |
Why?
|
| Mice | 1 | 2008 | 11193 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 2680 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1214 | 0.030 |
Why?
|
| Oklahoma | 1 | 2012 | 6 | 0.020 |
Why?
|
| Colposcopy | 1 | 2012 | 20 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 3782 | 0.020 |
Why?
|
| Decision Making | 1 | 2015 | 420 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 499 | 0.020 |
Why?
|
| Animals | 1 | 2008 | 21500 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 12 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1281 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 60 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 134 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 250 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 87 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 221 | 0.020 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 53 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 3373 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 2007 | 68 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 376 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 163 | 0.020 |
Why?
|
| Weight Loss | 1 | 2009 | 279 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 863 | 0.020 |
Why?
|
| United States | 1 | 2019 | 8149 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1156 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2007 | 365 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 2706 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 1122 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 2798 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 2645 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 5437 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2008 | 5824 | 0.010 |
Why?
|